476830 (476830)
KRX SM KRX SM Primary Summary
476830 Chart
476830 (476830) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 476830 ever had a stock split?
476830 Profile
| - Industry | - Sector | Mr. Seong-Wook Lee CEO | KRX SM Exchange | - ISIN |
| South Korea Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Rznomics Inc. is an innovative biotechnology firm that specializes in the development of RNA-based gene therapies targeting cancers and difficult-to-treat diseases. Founded in 2017, the company is situated in Seongnam-si, South Korea, and is focused on advancing clinical research aimed at providing effective treatments for various medical conditions, leveraging the transformative potential of RNA technology. With several product candidates at different stages of development, Rznomics aims to address significant unmet medical needs in oncology and other therapeutic areas.
Products and Services
- RZ-001 (Immune Therapy Combination)
This product candidate is currently in the Phase 1b/2a clinical stage and is aimed at treating Hepatocellular carcinoma, a primary form of liver cancer. The therapy integrates innovative RNA-based mechanisms to enhance the body's immune response against cancer cells.
- RZ-001 (GBM)
In the Phase 1/2a stage, this candidate focuses on Glioblastoma, an aggressive form of brain cancer. The therapeutic approach is designed to manipulate RNA pathways to improve patient outcomes and potentially prolong survival rates.
- RZ-003
This candidate is currently in the discovery stage and targets Alzheimer’s disease, a debilitating neurodegenerative condition. Rznomics aims to leverage RNA-based therapies to slow or halt the progression of cognitive decline associated with this disease.
- RZ-004
RZ-004 is in the pre-clinical stage and is focused on Retinitis Pigmentosa, a genetic disorder that leads to progressive retinal degeneration and vision loss. The goal is to utilize RNA technology to intervene and potentially restore vision in affected patients.
- RZ-005
This product is currently in the discovery stage, targeting Rett Syndrome, a rare genetic disorder that primarily affects females and leads to severe cognitive and physical impairments. Rznomics is exploring RNA-based strategies to mitigate the symptoms and improve the quality of life for patients suffering from this condition.
